Drug intelligence / Profile preview

celecoxib, naproxen + esomeprazole, acetaminophen + tramadol, oxycodone + naloxone

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

This combination describes a **list of four pharmaceutical products**, three of which are **combination drugs**: - **Celecoxib** is a selective COX-2 inhibitor (NSAID) for pain and inflammation, particularly in arthritis. - **Naproxen + esomeprazole** is a fixed-dose combination used primarily for arthritis. Naproxen is a nonselective NSAID, and esomeprazole is a proton pump inhibitor (PPI) included to reduce stomach acid and lower the risk of ulcers related to NSAID use. This combination is marketed as Vimovo and is indicated for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, especially in patients at risk for gastric ulcers[1][3][5][9]. - **Acetaminophen + tramadol** is a combination analgesic used for short-term treatment of moderate-to-severe acute pain. Tramadol is a centrally acting opioid receptor agonist with weak opioid activity, and acetaminophen is a non-opioid analgesic. The combination is intended to provide synergistic pain relief with lower doses of each component, potentially reducing the risk of side effects[2][4][6][8][10]. - **Oxycodone + naloxone** is an opioid analgesic/narcotic antagonist combination. Oxycodone is a potent opioid agonist, and naloxone is included to reduce opioid-induced constipation and deter abuse via non-oral routes. This combination is used for chronic severe pain requiring long-term opioid treatment and where alternative options are inadequate.

Brand names
CelebrexVimovoUltracetTramacetTarginTarginiq ER
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)MOR (Mu opioid receptor)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on celecoxib, naproxen + esomeprazole, acetaminophen + tramadol, oxycodone + naloxone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on celecoxib, naproxen + esomeprazole, acetaminophen + tramadol, oxycodone + naloxone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call